Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea

Joon-Young Song, Hee-Jin Cheong, Jung Yeon Heo, Ji Yun Noh, Wonseok Choi, Dae Won Park, Jacob Lee, Hye Won Jeong, Sae Yoon Kee, Woo Joo Kim

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The 2009 influenza pandemic was caused by a novel triple-reassortant influenza A/H1N1 virus that was further recombined with a Eurasian pig flu virus. Vaccination is a key countermeasure for disease; however, little data assessing vaccine effectiveness (VE) against the pandemic H1N1 virus are available. We conducted a matched case-control study to assess effectiveness of the 2009 influenza A/H1N1 monovalent vaccine against laboratory-confirmed, medically attended influenza patients. Subjects included in the study were ≥10 years of age and were treated at five university hospitals in the Republic of Korea (ROK) from December 2009 through March 2010. For subjects visiting outpatient clinics with influenza-like illness (ILI), real time reverse transcription polymerase chain reaction (rRT-PCR) was used to diagnose 2009 H1N1 influenza virus infection. Subjects with positive rRT-PCR were classified as cases, while those testing negative were controls. A valid vaccination corresponded to ≥14 days between receiving a dose of vaccine and symptom onset. Overall, 416 ILI subjects were analyzed, and 60 (14.4%) were vaccinated with the 2009 influenza A/H1N1 monovalent vaccine. The overall VE against pandemic 2009 A/H1N1 virus illness after adjustment for age group and presence of chronic medical conditions was 73.4% (95% confidence interval [CI] = 49.1-86.1%). Both vaccine formulations (unadjuvanted and MF-59 adjuvanted) showed a statistically significant VE. In conclusion, the 2009 influenza A/H1N1 monovalent vaccine was substantially protective against pandemic influenza in the ROK during the 2009-2010 season.

Original languageEnglish
Pages (from-to)1395-1398
Number of pages4
JournalVaccine
Volume29
Issue number7
DOIs
Publication statusPublished - 2011 Feb 4

Fingerprint

Pandemics
pandemic
Korea
influenza
Human Influenza
Korean Peninsula
Vaccines
vaccines
H1N1 Subtype Influenza A Virus
Republic of Korea
Influenza A virus
Reverse Transcription
South Korea
Vaccination
Polymerase Chain Reaction
reverse transcriptase polymerase chain reaction
vaccination
Virus Diseases
Ambulatory Care Facilities
Orthomyxoviridae

Keywords

  • 2009 H1N1
  • Effectiveness
  • Influenza
  • Vaccination

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea. / Song, Joon-Young; Cheong, Hee-Jin; Heo, Jung Yeon; Noh, Ji Yun; Choi, Wonseok; Park, Dae Won; Lee, Jacob; Jeong, Hye Won; Kee, Sae Yoon; Kim, Woo Joo.

In: Vaccine, Vol. 29, No. 7, 04.02.2011, p. 1395-1398.

Research output: Contribution to journalArticle

@article{1738984ab8be4326a526e01cd1e872c1,
title = "Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea",
abstract = "The 2009 influenza pandemic was caused by a novel triple-reassortant influenza A/H1N1 virus that was further recombined with a Eurasian pig flu virus. Vaccination is a key countermeasure for disease; however, little data assessing vaccine effectiveness (VE) against the pandemic H1N1 virus are available. We conducted a matched case-control study to assess effectiveness of the 2009 influenza A/H1N1 monovalent vaccine against laboratory-confirmed, medically attended influenza patients. Subjects included in the study were ≥10 years of age and were treated at five university hospitals in the Republic of Korea (ROK) from December 2009 through March 2010. For subjects visiting outpatient clinics with influenza-like illness (ILI), real time reverse transcription polymerase chain reaction (rRT-PCR) was used to diagnose 2009 H1N1 influenza virus infection. Subjects with positive rRT-PCR were classified as cases, while those testing negative were controls. A valid vaccination corresponded to ≥14 days between receiving a dose of vaccine and symptom onset. Overall, 416 ILI subjects were analyzed, and 60 (14.4{\%}) were vaccinated with the 2009 influenza A/H1N1 monovalent vaccine. The overall VE against pandemic 2009 A/H1N1 virus illness after adjustment for age group and presence of chronic medical conditions was 73.4{\%} (95{\%} confidence interval [CI] = 49.1-86.1{\%}). Both vaccine formulations (unadjuvanted and MF-59 adjuvanted) showed a statistically significant VE. In conclusion, the 2009 influenza A/H1N1 monovalent vaccine was substantially protective against pandemic influenza in the ROK during the 2009-2010 season.",
keywords = "2009 H1N1, Effectiveness, Influenza, Vaccination",
author = "Joon-Young Song and Hee-Jin Cheong and Heo, {Jung Yeon} and Noh, {Ji Yun} and Wonseok Choi and Park, {Dae Won} and Jacob Lee and Jeong, {Hye Won} and Kee, {Sae Yoon} and Kim, {Woo Joo}",
year = "2011",
month = "2",
day = "4",
doi = "10.1016/j.vaccine.2010.12.050",
language = "English",
volume = "29",
pages = "1395--1398",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "7",

}

TY - JOUR

T1 - Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea

AU - Song, Joon-Young

AU - Cheong, Hee-Jin

AU - Heo, Jung Yeon

AU - Noh, Ji Yun

AU - Choi, Wonseok

AU - Park, Dae Won

AU - Lee, Jacob

AU - Jeong, Hye Won

AU - Kee, Sae Yoon

AU - Kim, Woo Joo

PY - 2011/2/4

Y1 - 2011/2/4

N2 - The 2009 influenza pandemic was caused by a novel triple-reassortant influenza A/H1N1 virus that was further recombined with a Eurasian pig flu virus. Vaccination is a key countermeasure for disease; however, little data assessing vaccine effectiveness (VE) against the pandemic H1N1 virus are available. We conducted a matched case-control study to assess effectiveness of the 2009 influenza A/H1N1 monovalent vaccine against laboratory-confirmed, medically attended influenza patients. Subjects included in the study were ≥10 years of age and were treated at five university hospitals in the Republic of Korea (ROK) from December 2009 through March 2010. For subjects visiting outpatient clinics with influenza-like illness (ILI), real time reverse transcription polymerase chain reaction (rRT-PCR) was used to diagnose 2009 H1N1 influenza virus infection. Subjects with positive rRT-PCR were classified as cases, while those testing negative were controls. A valid vaccination corresponded to ≥14 days between receiving a dose of vaccine and symptom onset. Overall, 416 ILI subjects were analyzed, and 60 (14.4%) were vaccinated with the 2009 influenza A/H1N1 monovalent vaccine. The overall VE against pandemic 2009 A/H1N1 virus illness after adjustment for age group and presence of chronic medical conditions was 73.4% (95% confidence interval [CI] = 49.1-86.1%). Both vaccine formulations (unadjuvanted and MF-59 adjuvanted) showed a statistically significant VE. In conclusion, the 2009 influenza A/H1N1 monovalent vaccine was substantially protective against pandemic influenza in the ROK during the 2009-2010 season.

AB - The 2009 influenza pandemic was caused by a novel triple-reassortant influenza A/H1N1 virus that was further recombined with a Eurasian pig flu virus. Vaccination is a key countermeasure for disease; however, little data assessing vaccine effectiveness (VE) against the pandemic H1N1 virus are available. We conducted a matched case-control study to assess effectiveness of the 2009 influenza A/H1N1 monovalent vaccine against laboratory-confirmed, medically attended influenza patients. Subjects included in the study were ≥10 years of age and were treated at five university hospitals in the Republic of Korea (ROK) from December 2009 through March 2010. For subjects visiting outpatient clinics with influenza-like illness (ILI), real time reverse transcription polymerase chain reaction (rRT-PCR) was used to diagnose 2009 H1N1 influenza virus infection. Subjects with positive rRT-PCR were classified as cases, while those testing negative were controls. A valid vaccination corresponded to ≥14 days between receiving a dose of vaccine and symptom onset. Overall, 416 ILI subjects were analyzed, and 60 (14.4%) were vaccinated with the 2009 influenza A/H1N1 monovalent vaccine. The overall VE against pandemic 2009 A/H1N1 virus illness after adjustment for age group and presence of chronic medical conditions was 73.4% (95% confidence interval [CI] = 49.1-86.1%). Both vaccine formulations (unadjuvanted and MF-59 adjuvanted) showed a statistically significant VE. In conclusion, the 2009 influenza A/H1N1 monovalent vaccine was substantially protective against pandemic influenza in the ROK during the 2009-2010 season.

KW - 2009 H1N1

KW - Effectiveness

KW - Influenza

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=79151474497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79151474497&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.12.050

DO - 10.1016/j.vaccine.2010.12.050

M3 - Article

C2 - 21199701

AN - SCOPUS:79151474497

VL - 29

SP - 1395

EP - 1398

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 7

ER -